Cortexyme | May 13, 2019

Cortexyme, Inc. announces closing of initial public offering and the exercise of the underwriters’ option to purchase additional shares

Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced…

Synbiobeta | April 16, 2019

Checkerspot raises $13M Series A to produce biotech-enabled performance materials

Checkerspot, a biotech startup using microalgae to produce performance materials, announced today that it has closed its Series A financing for $13 million. The round was led by Builders VC, and included Breakout Ventures…

Fast Company | Feb 14, 2019

This startup is tracking microbes to figure out where your shoes were really made

Because a microbiome can serve as a unique identifier of a place, Phylagen is gathering data from global factories so brands can better understand where their products are made, and detect if the work is being outsourced to places that rely on slavery or child labor….

Science Translational Medicine | Jan 25, 2019

A new infectious mechanism for Alzheimer’s?

We have another entry in the “Is Alzheimer’s caused by infectious disease?” drawing, and it’s a good one. A large multicenter team reports that Porphyromonas gingivalis, which is the key pathogen in gingivitis (gum disease) may be the actual causative agent in Alzheimer’s,…

NewScientist | Jan 23, 2019

We may finally know what causes Alzheimer’s – and how to stop it

After decades of disappointment, we may have a new lead on fighting Alzheimer’s disease. Compelling evidence that the condition is caused by a bacterium involved in gum disease could prove a game-changer in tackling one of medicine’s biggest mysteries, and lead to effective treatments or even a vaccine…

GeekWire | Jan 4, 2019

Seattle biotech startup raises $20M to develop gene therapy technology

Seattle-based biotech startup Immusoft this week closed a $20 million Series B venture capital round that will fuel development of its gene therapy technology. Founded in 2009, Immusoft develops immune cell technology that uses blood cells from a patient to create therapeutic proteins…

Fortune | Sep 17, 2017

These VCs are bringing 'Hard Science' to Fortune 500 companies

In 2010, as the dust from the financial crisis settled, three women working in disparate parts of the economy noticed that startups in “hard science” (think biology or chemistry rather than tech) weren’t getting the attention they deserved from big investors…

TechCrunch | Sep 14, 2017

Breakout Ventures, spun out of Peter Thiel’s Breakout Labs, has closed its debut fund with $60M

Lindy Fishburne has spent most of the last six years heading up Breakout Labs, a San Francisco-based program that’s underwritten by renowned investor Peter Thiel and that in 2011 began offering nascent science-focused startups up to $350,000 in funding with no strings attached…